argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
08 dec 2014 - 19:30
Statutaire naam
argenx SE
Titel
arGEN-X Reports Preclinical Data on ARGX-110 in Chronic Myelogenous Leukemia Model
Bericht
PRESS RELEASE: BIOTECHNOLOGY
Breda, The Netherlands - Gent, Belgium, 8 December 2014
Data to be presented at ASH demonstrate potential of ARGX-110 in reversing resistance to tyrosine kinase inhibitors
arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announces the presentation of preclinical data at the American Society of Hematology (ASH) Annual Meeting highlighting the potential of the CD70 pathway as a targetable mechanism to overcome drug resistance in chronic myelogenous leukemia (CML). The data show that co-treatment of ARGX-110, the Company's anti-CD70 therapeutic antibody, and imatinib, a first-line BCR/ABL-specific tyrosine kinase inhibitor (TKI), eradicates the disease-initiating CML stem cells, a cell population often resistant to TKI therapy.
Gerelateerde downloads
Datum laatste update: 02 september 2024